Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTELIGEO vs SYLVANT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).
Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.
Adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy
Treatment of multicentric Castleman disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,Off-label: Treatment of cytokine release syndrome, Castleman disease in HIV-positive or HHV-8-positive patients, and other IL-6-driven conditions.
3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.
11 mg/kg intravenously every 3 weeks, administered over 1 hour.
Terminal elimination half-life is approximately 17 days (range 11–22 days) at steady state, supporting every-2-week or every-4-week dosing intervals.
Terminal half-life ~21 days (range 14–28 days) at steady state; supports every-3-week dosing.
Mogamulizumab is a monoclonal antibody; metabolism is via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes identified.
Siltuximab is a monoclonal antibody; its metabolism is not typical. It is degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. No specific metabolic enzymes are involved.
POTELIGEO (mogamulizumab) is a monoclonal antibody, primarily eliminated via intracellular catabolism into amino acids. No quantitative data on renal or biliary excretion; minimal to no excretion as intact antibody in urine or feces.
Renal (minimal as intact Ig G), primarily catabolized to amino acids; no significant biliary/fecal elimination.
Approximately 95% bound to plasma proteins, predominantly to immunoglobulins and albumin as a therapeutic monoclonal antibody.
No specific protein binding; Ig G4 monoclonal antibody does not bind significantly to plasma proteins.
Volume of distribution at steady state (Vss) is approximately 5.1 L (range 3.8–6.7 L), indicative of limited extravascular distribution, consistent with a monoclonal antibody primarily confined to vascular and interstitial spaces.
Vd ~6.0 L (0.08 L/kg for 70 kg adult); primarily confined to vascular space and interstitial fluid.
Only intravenous administration; intravenous bioavailability is 100% by definition.
IV administration: 100% bioavailable; no other routes approved.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl 30-89 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD.
No dose adjustment required for Child-Pugh A or B. Insufficient data for Child-Pugh C. Use with caution.
No formal studies in hepatic impairment. Use with caution in patients with moderate to severe impairment (Child-Pugh B or C).
Safety and effectiveness not established in pediatric patients.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended. Monitor for adverse effects more frequently due to potential age-related renal and hepatic function decline.
No specific dose adjustment recommended; select dose with caution due to higher frequency of decreased hepatic, renal, or cardiac function and concomitant disease or drug therapy.
WARNING: DERMATOLOGIC TOXICITY. Severe, including fatal, dermatologic adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred. Discontinue for suspected severe cutaneous adverse reactions.
None.
Infusion reactions: Monitor during infusion; interrupt or discontinue based on severity.,Dermatologic toxicity: Severe skin reactions including SJS/TEN; discontinue if suspected.,Immune-mediated adverse reactions: including pneumonitis, hepatitis, colitis, endocrinopathies, and others.,Infections: Fatal infections occurred; monitor for infections and treat promptly.,Autoimmune hemolytic anemia: Fatal cases reported.,Posterior reversible encephalopathy syndrome (PRES): Discontinue if suspected.,Hematologic toxicity: Monitor blood counts; severe neutropenia, thrombocytopenia, and anemia reported.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Risk of serious infections: Evaluate for active infections prior to initiating therapy; monitor for infections during treatment.,Hypersensitivity reactions: Infusion-related reactions may occur; premedicate and monitor during infusion.,Hematologic effects: Neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts.,Hepatotoxicity: Elevations of liver enzymes have been reported; monitor liver function.,Immunogenicity: Anti-drug antibodies may develop and affect efficacy or safety.,Vaccinations: Live vaccines should not be administered during treatment.
None
Known severe hypersensitivity to siltuximab or any of its excipients.,Active severe infections until infection is controlled.
No known food interactions. Grapefruit or other CYP inhibitors/inducers are not expected to affect mogamulizumab as it is a monoclonal antibody cleared via proteolysis. No dietary restrictions necessary.
No clinically significant food interactions have been reported. Take with or without food as tolerated.
POTELIGEO (mogamulizumab) is a monoclonal antibody. Ig G antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on its mechanism of action (CCR4-directed cytolytic activity), there is potential for fetal harm, including depletion of maternal and fetal T-cell subsets, especially regulatory T cells, which are critical for immune tolerance. Animal studies have not been conducted, but given the pharmacodynamics, use during pregnancy should be avoided unless clearly necessary. First trimester exposure carries theoretical risks of altered immune development; second and third trimester exposure may cause fetal lymphopenia and increased infection risk.
SYLVANT (siltuximab) is a monoclonal antibody (Ig G1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Animal studies have shown no evidence of teratogenicity in cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, there are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (IL-6 inhibition), there is a potential risk of fetal harm due to interference with normal immune development and hematopoiesis. Therefore, SYLVANT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is unknown whether mogamulizumab is excreted in human milk. Human Ig G is present in breast milk, but concentrations are generally low. The M/P ratio has not been determined. Due to the potential for serious adverse reactions in the breastfed infant (e.g., immunosuppression), women should not breastfeed during treatment and for at least 5 half-lives (approximately 5 weeks) after the last dose.
It is not known whether siltuximab is excreted in human milk. However, maternal Ig G is known to be present in breast milk, and monoclonal antibodies can be excreted in low amounts. The M/P ratio is not available. The effects on the breastfed infant and on milk production are unknown. Because of the potential for adverse reactions in nursing infants from siltuximab, breastfeeding should be discontinued during treatment and for at least 90 days after the last dose.
No pharmacokinetic studies in pregnancy. Dosing adjustments are not established; however, physiologic changes in pregnancy (e.g., increased plasma volume, altered clearance) may affect pharmacokinetics. Given the monoclonal antibody, no dose adjustment is recommended, but clinical monitoring for efficacy and toxicity should be considered. Use only if potential benefit justifies potential risk.
No specific dose adjustments are recommended for SYLVANT during pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) may occur, but no data are available to guide adjustments. The drug should be used with caution, and the dose should be guided by clinical response and tolerability.
Poteligeo (mogamulizumab) is a humanized anti-CCR4 monoclonal antibody used for adult T-cell leukemia-lymphoma (ATLL) and mycosis fungoides (MF)/Sézary syndrome (SS). It depletes CCR4-expressing T cells, including regulatory T cells (Tregs), which may exacerbate graft-versus-host disease (GVHD) after transplant. Monitor for infusion reactions and severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome). Dose reduction for creatinine clearance <30 m L/min is not established; avoid in severe renal impairment. Premedicate with antihistamines and acetaminophen. Live vaccines contraindicated during and after treatment.
SYLVANT (siltuximab) is an IL-6 antagonist indicated for idiopathic multicentric Castleman disease (MCD). Monitor for infections due to immunosuppression; do not administer live vaccines. Infusion reactions possible; premedicate with antihistamines/acetaminophen if needed. Assess baseline hepatic function, as transaminase elevations may occur. Discontinue if severe infusion reaction or anaphylaxis.
Poteligeo can cause severe skin reactions; report any rash, blisters, or peeling skin immediately.,You may experience infusion reactions (fever, chills, nausea) during or after infusion; premedication will be given.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for at least 1 year after last dose.,Do not breastfeed while on Poteligeo and for at least 2 months after last dose.,Use effective birth control during treatment and for at least 3 months after last dose.,Notify your doctor if you have a history of organ transplant or are planning a transplant.,Poteligeo can lower your immune system; report signs of infection (fever, cough, sore throat).
Report signs of infection (fever, chills, sore throat) immediately.,Avoid live vaccines (e.g., MMR, varicella) during treatment and for 3 months after.,Notify your doctor if you experience symptoms of infusion reaction (headache, nausea, dizziness, rash).,Regular blood tests will be required to monitor liver function and blood counts.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTELIGEO vs SYLVANT, answered by our medical review team.
POTELIGEO is a Monoclonal Antibody Antineoplastic that works by Mogamulizumab is a defucosylated humanized anti-CCR4 monoclonal antibody that binds to CCR4 on the surface of cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and depleting CCR4-expressing cells, including malignant T cells and regulatory T cells (Tregs).. SYLVANT is a Monoclonal Antibody Antineoplastic that works by Siltuximab is a chimeric monoclonal antibody that binds to human interleukin-6 (IL-6) and prevents its binding to the IL-6 receptor, thereby inhibiting IL-6-mediated signaling and the downstream inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTELIGEO and SYLVANT depend on the specific clinical indication. These are both Monoclonal Antibody Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTELIGEO is: 3 mg/kg intravenously over 60 minutes on days 1, 8, and 15 of each 28-day cycle.. The standard adult dose of SYLVANT is: 11 mg/kg intravenously every 3 weeks, administered over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTELIGEO and SYLVANT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTELIGEO is classified as Category C. POTELIGEO (mogamulizumab) is a monoclonal antibody. IgG antibodies cross the placenta increasingly after the first trimester, with peak transfer in the third trimester. Based on it. SYLVANT is classified as Category C. SYLVANT (siltuximab) is a monoclonal antibody (IgG1) that crosses the placenta in increasing amounts as pregnancy progresses, with the highest transfer in the third trimester. Anim. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.